Stiff person syndrome with Anti‐GAD65 antibodies within the national veterans affairs health administration
ABSTRACT Introduction: Stiff person syndrome (SPS) is a neurological disorder characterized by muscle rigidity primarily in the truncal muscles, commonly associated with autoantibodies to the glutamic acid‐decarboxylase 65 kD receptor (GAD65). There is limited epidemiological information on patients...
Gespeichert in:
| Veröffentlicht in: | Muscle & nerve 2018-12, Vol.58 (6), p.801-804 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 804 |
|---|---|
| container_issue | 6 |
| container_start_page | 801 |
| container_title | Muscle & nerve |
| container_volume | 58 |
| creator | Galli, Jonathan R. Austin, Sharon D. Greenlee, John E. Clardy, Stacey L. |
| description | ABSTRACT
Introduction: Stiff person syndrome (SPS) is a neurological disorder characterized by muscle rigidity primarily in the truncal muscles, commonly associated with autoantibodies to the glutamic acid‐decarboxylase 65 kD receptor (GAD65). There is limited epidemiological information on patients with SPS. Methods: We performed a retrospective case review using the National United States Veterans Affairs Health Administration electronic medical record system. We analyzed prevalence, demographics, disease characteristics, and treatment outcomes in SPS patients who were anti‐GAD65 antibody positive. Results: Fifteen patients met our criteria. Point prevalence was 2.06 per million, and period prevalence was 2.71 per million. Men to women ratio was 14:1. All patients benefitted from treatment with symptomatic antispasmodic agents. Ten of 15 patients received intravenous immunoglobulin, with a majority demonstrating stable or improved modified Rankin scores. Discussion: This investigation was a large North American epidemiological study of SPS with predominantly male patients. Symptomatic therapy was beneficial for most patients, with less clear sustained benefit of immunotherapy. Muscle Nerve 58:801–804, 2018 |
| doi_str_mv | 10.1002/mus.26338 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2101276441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2157328996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-c138bf6be1d57bec63ff151241bd7c000d3a4f65fc9770b8a2296a8f6b1e4ec53</originalsourceid><addsrcrecordid>eNp10ctKxDAUgOEgio6jC19AAm50USeXNkmXg3dQXKjgrqTtCRNp0zFpldn5CD6jT2LGUReCqxDy5YfkILRHyTElhE3aIRwzwblaQyNKcpmkWa7W0YjQVCWC549baDuEJ0IIVUJuoi1OaM4IkyPU3vXWGDwHHzqHw8LVvmsBv9p-hqeutx9v7xfTU5FhHTdlV1sIX4fW4X4G2Onedk43-AV68NoFrI3R1gc8A93Ehq5b62zo_RfcQRtGNwF2v9cxejg_uz-5TK5vL65OptdJxTOukopyVRpRAq0zWUIluDE0oyylZS2r-Iya69SIzFS5lKRUmrFcaBVvUEihyvgYHa66c989DxD6orWhgqbRDrohFIwSyqRIUxrpwR_61A0-PmmpMsmZynMR1dFKVb4LwYMp5t622i8KSorlDIp2mV3OINr97-JQtlD_yp9Pj2CyAq-2gcX_peLm4W6V_ATTnZKb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157328996</pqid></control><display><type>article</type><title>Stiff person syndrome with Anti‐GAD65 antibodies within the national veterans affairs health administration</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Galli, Jonathan R. ; Austin, Sharon D. ; Greenlee, John E. ; Clardy, Stacey L.</creator><creatorcontrib>Galli, Jonathan R. ; Austin, Sharon D. ; Greenlee, John E. ; Clardy, Stacey L.</creatorcontrib><description>ABSTRACT
Introduction: Stiff person syndrome (SPS) is a neurological disorder characterized by muscle rigidity primarily in the truncal muscles, commonly associated with autoantibodies to the glutamic acid‐decarboxylase 65 kD receptor (GAD65). There is limited epidemiological information on patients with SPS. Methods: We performed a retrospective case review using the National United States Veterans Affairs Health Administration electronic medical record system. We analyzed prevalence, demographics, disease characteristics, and treatment outcomes in SPS patients who were anti‐GAD65 antibody positive. Results: Fifteen patients met our criteria. Point prevalence was 2.06 per million, and period prevalence was 2.71 per million. Men to women ratio was 14:1. All patients benefitted from treatment with symptomatic antispasmodic agents. Ten of 15 patients received intravenous immunoglobulin, with a majority demonstrating stable or improved modified Rankin scores. Discussion: This investigation was a large North American epidemiological study of SPS with predominantly male patients. Symptomatic therapy was beneficial for most patients, with less clear sustained benefit of immunotherapy. Muscle Nerve 58:801–804, 2018</description><identifier>ISSN: 0148-639X</identifier><identifier>EISSN: 1097-4598</identifier><identifier>DOI: 10.1002/mus.26338</identifier><identifier>PMID: 30192027</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antibodies ; Autoantibodies ; Demographics ; Demography ; Electronic health records ; Electronic medical records ; Epidemiology ; GAD65 ; Glutamic acid ; Glutamic acid receptors ; Health services ; Immunotherapy ; Intravenous administration ; Medical treatment ; Muscle relaxants ; Muscles ; Parasympathetic nervous system ; Patients ; Rigidity ; stiff man syndrome ; stiff person syndrome</subject><ispartof>Muscle & nerve, 2018-12, Vol.58 (6), p.801-804</ispartof><rights>2018 Wiley Periodicals, Inc</rights><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-c138bf6be1d57bec63ff151241bd7c000d3a4f65fc9770b8a2296a8f6b1e4ec53</citedby><cites>FETCH-LOGICAL-c3538-c138bf6be1d57bec63ff151241bd7c000d3a4f65fc9770b8a2296a8f6b1e4ec53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmus.26338$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmus.26338$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30192027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galli, Jonathan R.</creatorcontrib><creatorcontrib>Austin, Sharon D.</creatorcontrib><creatorcontrib>Greenlee, John E.</creatorcontrib><creatorcontrib>Clardy, Stacey L.</creatorcontrib><title>Stiff person syndrome with Anti‐GAD65 antibodies within the national veterans affairs health administration</title><title>Muscle & nerve</title><addtitle>Muscle Nerve</addtitle><description>ABSTRACT
Introduction: Stiff person syndrome (SPS) is a neurological disorder characterized by muscle rigidity primarily in the truncal muscles, commonly associated with autoantibodies to the glutamic acid‐decarboxylase 65 kD receptor (GAD65). There is limited epidemiological information on patients with SPS. Methods: We performed a retrospective case review using the National United States Veterans Affairs Health Administration electronic medical record system. We analyzed prevalence, demographics, disease characteristics, and treatment outcomes in SPS patients who were anti‐GAD65 antibody positive. Results: Fifteen patients met our criteria. Point prevalence was 2.06 per million, and period prevalence was 2.71 per million. Men to women ratio was 14:1. All patients benefitted from treatment with symptomatic antispasmodic agents. Ten of 15 patients received intravenous immunoglobulin, with a majority demonstrating stable or improved modified Rankin scores. Discussion: This investigation was a large North American epidemiological study of SPS with predominantly male patients. Symptomatic therapy was beneficial for most patients, with less clear sustained benefit of immunotherapy. Muscle Nerve 58:801–804, 2018</description><subject>Antibodies</subject><subject>Autoantibodies</subject><subject>Demographics</subject><subject>Demography</subject><subject>Electronic health records</subject><subject>Electronic medical records</subject><subject>Epidemiology</subject><subject>GAD65</subject><subject>Glutamic acid</subject><subject>Glutamic acid receptors</subject><subject>Health services</subject><subject>Immunotherapy</subject><subject>Intravenous administration</subject><subject>Medical treatment</subject><subject>Muscle relaxants</subject><subject>Muscles</subject><subject>Parasympathetic nervous system</subject><subject>Patients</subject><subject>Rigidity</subject><subject>stiff man syndrome</subject><subject>stiff person syndrome</subject><issn>0148-639X</issn><issn>1097-4598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp10ctKxDAUgOEgio6jC19AAm50USeXNkmXg3dQXKjgrqTtCRNp0zFpldn5CD6jT2LGUReCqxDy5YfkILRHyTElhE3aIRwzwblaQyNKcpmkWa7W0YjQVCWC549baDuEJ0IIVUJuoi1OaM4IkyPU3vXWGDwHHzqHw8LVvmsBv9p-hqeutx9v7xfTU5FhHTdlV1sIX4fW4X4G2Onedk43-AV68NoFrI3R1gc8A93Ehq5b62zo_RfcQRtGNwF2v9cxejg_uz-5TK5vL65OptdJxTOukopyVRpRAq0zWUIluDE0oyylZS2r-Iya69SIzFS5lKRUmrFcaBVvUEihyvgYHa66c989DxD6orWhgqbRDrohFIwSyqRIUxrpwR_61A0-PmmpMsmZynMR1dFKVb4LwYMp5t622i8KSorlDIp2mV3OINr97-JQtlD_yp9Pj2CyAq-2gcX_peLm4W6V_ATTnZKb</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Galli, Jonathan R.</creator><creator>Austin, Sharon D.</creator><creator>Greenlee, John E.</creator><creator>Clardy, Stacey L.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201812</creationdate><title>Stiff person syndrome with Anti‐GAD65 antibodies within the national veterans affairs health administration</title><author>Galli, Jonathan R. ; Austin, Sharon D. ; Greenlee, John E. ; Clardy, Stacey L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-c138bf6be1d57bec63ff151241bd7c000d3a4f65fc9770b8a2296a8f6b1e4ec53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antibodies</topic><topic>Autoantibodies</topic><topic>Demographics</topic><topic>Demography</topic><topic>Electronic health records</topic><topic>Electronic medical records</topic><topic>Epidemiology</topic><topic>GAD65</topic><topic>Glutamic acid</topic><topic>Glutamic acid receptors</topic><topic>Health services</topic><topic>Immunotherapy</topic><topic>Intravenous administration</topic><topic>Medical treatment</topic><topic>Muscle relaxants</topic><topic>Muscles</topic><topic>Parasympathetic nervous system</topic><topic>Patients</topic><topic>Rigidity</topic><topic>stiff man syndrome</topic><topic>stiff person syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galli, Jonathan R.</creatorcontrib><creatorcontrib>Austin, Sharon D.</creatorcontrib><creatorcontrib>Greenlee, John E.</creatorcontrib><creatorcontrib>Clardy, Stacey L.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Muscle & nerve</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galli, Jonathan R.</au><au>Austin, Sharon D.</au><au>Greenlee, John E.</au><au>Clardy, Stacey L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stiff person syndrome with Anti‐GAD65 antibodies within the national veterans affairs health administration</atitle><jtitle>Muscle & nerve</jtitle><addtitle>Muscle Nerve</addtitle><date>2018-12</date><risdate>2018</risdate><volume>58</volume><issue>6</issue><spage>801</spage><epage>804</epage><pages>801-804</pages><issn>0148-639X</issn><eissn>1097-4598</eissn><abstract>ABSTRACT
Introduction: Stiff person syndrome (SPS) is a neurological disorder characterized by muscle rigidity primarily in the truncal muscles, commonly associated with autoantibodies to the glutamic acid‐decarboxylase 65 kD receptor (GAD65). There is limited epidemiological information on patients with SPS. Methods: We performed a retrospective case review using the National United States Veterans Affairs Health Administration electronic medical record system. We analyzed prevalence, demographics, disease characteristics, and treatment outcomes in SPS patients who were anti‐GAD65 antibody positive. Results: Fifteen patients met our criteria. Point prevalence was 2.06 per million, and period prevalence was 2.71 per million. Men to women ratio was 14:1. All patients benefitted from treatment with symptomatic antispasmodic agents. Ten of 15 patients received intravenous immunoglobulin, with a majority demonstrating stable or improved modified Rankin scores. Discussion: This investigation was a large North American epidemiological study of SPS with predominantly male patients. Symptomatic therapy was beneficial for most patients, with less clear sustained benefit of immunotherapy. Muscle Nerve 58:801–804, 2018</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30192027</pmid><doi>10.1002/mus.26338</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0148-639X |
| ispartof | Muscle & nerve, 2018-12, Vol.58 (6), p.801-804 |
| issn | 0148-639X 1097-4598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2101276441 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies Autoantibodies Demographics Demography Electronic health records Electronic medical records Epidemiology GAD65 Glutamic acid Glutamic acid receptors Health services Immunotherapy Intravenous administration Medical treatment Muscle relaxants Muscles Parasympathetic nervous system Patients Rigidity stiff man syndrome stiff person syndrome |
| title | Stiff person syndrome with Anti‐GAD65 antibodies within the national veterans affairs health administration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A50%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stiff%20person%20syndrome%20with%20Anti%E2%80%90GAD65%20antibodies%20within%20the%20national%20veterans%20affairs%20health%20administration&rft.jtitle=Muscle%20&%20nerve&rft.au=Galli,%20Jonathan%20R.&rft.date=2018-12&rft.volume=58&rft.issue=6&rft.spage=801&rft.epage=804&rft.pages=801-804&rft.issn=0148-639X&rft.eissn=1097-4598&rft_id=info:doi/10.1002/mus.26338&rft_dat=%3Cproquest_cross%3E2157328996%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157328996&rft_id=info:pmid/30192027&rfr_iscdi=true |